Middle East Erupts Again: Buy these Healthcare ETFs Before the Next StrikeZacks Investment Research • 06/09/26
Forget Nvidia and SpaceX. This 150-Year-Old Indiana Company Could Become the World's Largest in 5 Years24/7 Wall Street • 06/09/26
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic ConditionsBusiness Wire • 06/09/26
The space race is coming for pharma: Why drug development is heading to lower Earth orbitCNBC • 06/09/26
Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning AnywayThe Motley Fool • 06/08/26
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?The Motley Fool • 06/08/26
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialsPRNewsWire • 06/08/26
Why Eli Lilly, In A Buy Zone, Is Still The 'Clear Winner' Of The 'Weight Loss Olympics'Investors Business Daily • 06/08/26
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.The Motley Fool • 06/08/26
Novo Nordisk Real-World Data Supports Ozempic Against LLY's MounjaroZacks Investment Research • 06/08/26
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverageCNBC • 06/08/26
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drugMarket Watch • 06/08/26
Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.Barrons • 06/08/26
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopausePRNewsWire • 06/07/26
Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.Market Watch • 06/06/26